HCG vs PT-141.

Human chorionic gonadotropin (HCG) is a naturally occurring glycoprotein hormone produced by the placenta during pregnancy, and it is also manufactured as an FDA-approved injectable medicine. As a drug it is sold under brand names such as Pregnyl and Novarel (purified from urine) and Ovidrel (recombinant). It is used in reproductive and endocrine medicine rather than as a research peptide. Because its activity closely mimics luteinizing hormone (LH), it is used to stimulate the gonads in both males and females.

PT-141, generic name bremelanotide, is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It originated from work on the tanning peptide melanotan II (and is closely related to a melanotan-II metabolite, differing chiefly by a hydroxyl rather than an amide group), refined by Palatin Technologies to favor sexual-function effects over skin pigmentation. As the prescription product Vyleesi, it is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

HCG shares strong structural similarity with LH and binds the LH/HCG receptor, effectively acting as an LH agonist. In males, this stimulates the Leydig cells of the testes to produce testosterone and can support spermatogenesis; in prepubertal boys with cryptorchidism it can promote testicular descent. In females undergoing fertility treatment, HCG triggers final oocyte maturation and ovulation after follicular development. These direct effects on the gonads are the basis for its approved clinical uses.

Bremelanotide is a non-selective agonist of melanocortin receptors with activity at MC1R through MC5R, but its therapeutic effect is attributed primarily to central MC4R (and MC3R) activation in hypothalamic and limbic brain regions that govern sexual motivation and arousal. Unlike PDE5 inhibitors or hormonal agents, it acts on central nervous system pathways rather than directly on vascular or genital tissue, and is thought to modulate dopaminergic signaling in motivation circuits. The FDA label explicitly states that the precise mechanism by which it improves sexual desire and related distress is not fully known. Its activity at peripheral melanocortin receptors (e.g., MC1R) also explains off-target effects such as skin hyperpigmentation and transient cardiovascular changes.

HCG has decades of established clinical use, and its FDA-approved indications are supported by its long regulatory and prescribing history rather than by a single pivotal trial. Approved uses include prepubertal cryptorchidism not due to anatomic obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in carefully selected infertile women as part of assisted reproduction. In men, it is also used clinically to preserve testicular function and fertility, though some such uses are off-label. Much of this evidence base predates modern trial standards, so the supporting literature is a mixture of older controlled studies, registry and clinic series, and specialty guidance rather than large contemporary randomised trials with adjudicated endpoints. Notably, the FDA-approved labeling explicitly states there is no substantial evidence that HCG is effective for weight loss or fat redistribution, and it is not approved for weight loss. The weight-loss claim has actually been tested. A criteria-based meta-analysis published in the British Journal of Clinical Pharmacology in 1995 assessed controlled trials of HCG for obesity under the Simeons regimen and concluded that the evidence did not support an effect of HCG on weight loss, fat distribution, hunger or wellbeing. Where weight loss was observed in such programs, it is attributable to the severe caloric restriction that accompanied the injections rather than to the hormone. This contrasts sharply with actual obesity pharmacotherapy, where agents such as GLP-1 receptor agonists were approved on the basis of large randomised, double-blind, placebo-controlled Phase 3 trials with prespecified weight endpoints, and in some cases dedicated cardiovascular outcome trials. HCG has no comparable evidence for weight management. Its efficacy and safety for its endocrine and fertility indications are well characterized in the drug label and clinical guidelines.

The strongest human evidence comes from the two identical phase 3 RECONNECT trials (Kingsberg et al., Obstetrics & Gynecology, 2019), randomized, double-blind, placebo-controlled studies in premenopausal women with HSDD that used co-primary endpoints of change in the FSFI desire domain and the FSDS-DAO Item 13 distress score; both showed statistically significant but modest improvements over placebo (integrated desire change ~0.35, distress change ~-0.33, p<0.001), with an open-label extension reporting longer-term safety (Simon et al., Obstet Gynecol 2019). Independent re-analyses (e.g., Spielmans, Journal of Sex Research 2021) argue the effect sizes are small and of uncertain clinical meaningfulness, and roughly 40% of trial participants discontinued. For male sexual dysfunction and other proposed uses, human data are far thinner: earlier intranasal bremelanotide erectile-dysfunction programs were halted partly over blood-pressure concerns, and claims about libido enhancement in men or in postmenopausal women rest largely on small, older, or preclinical studies rather than robust randomized trials. There is no approved or well-evidenced use outside premenopausal-female HSDD.

Recognized risks include ovarian hyperstimulation syndrome and increased chance of multiple pregnancy when used for ovulation induction, as well as injection-site reactions, headache, fatigue, mood changes, gynecomastia, and, rarely, arterial thromboembolism. HCG should not be used during pregnancy and requires medical supervision, particularly in patients with conditions sensitive to sex-steroid changes. Because HCG acts as an LH analogue, it raises endogenous sex-steroid production, so supervised use typically involves baseline and follow-up hormone testing, and in fertility settings ultrasound follicle monitoring and estradiol measurement precisely because ovarian hyperstimulation can escalate quickly and is occasionally severe. In males, prolonged stimulation can raise estradiol and affect the testosterone to estradiol balance, which is one reason clinical use is monitored rather than open-ended. Precocious puberty is a labelled concern when used in prepubertal boys. The labeling specifically warns against use for weight loss, including so-called 'HCG diet' regimens, which are not supported by evidence and may be paired with unsafe very-low-calorie dieting; the caloric restriction itself carries risks including nutrient deficiency, gallstones, electrolyte disturbance and loss of lean mass. A further hazard is supply. Over-the-counter, homeopathic and online HCG weight-loss products are unapproved, and injectable material obtained outside a pharmacy has no verified potency, purity or sterility, so unsupervised use adds an unregulated-product risk on top of a hormone that already needs clinical oversight.

The most common adverse effects in trials were nausea (around 40%), flushing, injection-site reactions, and headache; nausea was a frequent reason for discontinuation. Bremelanotide transiently raises blood pressure (peak systolic increase of about 6 mm Hg) and lowers heart rate for several hours after each dose, and the FDA label contraindicates it in people with uncontrolled hypertension or known cardiovascular disease and advises against use in those at high cardiovascular risk. Focal hyperpigmentation of the face, gingiva, and breasts occurred in about 1% of treated patients and becomes more likely with more frequent dosing, and may not fully resolve. Safety beyond the studied population (men, postmenopausal women, and people using non-pharmaceutical "research" peptide products of unverified purity) is not established, and gray-market injectable PT-141 carries additional risks of contamination and inaccurate content.

HCG is FDA-approved as a prescription injectable for specified endocrine and fertility indications (e.g., Pregnyl, Novarel, Ovidrel). The FDA has stated that HCG is not approved and lacks substantial evidence for weight loss, and over-the-counter 'homeopathic' HCG weight-loss products are considered unapproved and illegal. It is a prescription-only medicine that requires clinical oversight.

Bremelanotide was FDA-approved in June 2019 as Vyleesi (subcutaneous injection) for acquired, generalized HSDD in premenopausal women, and is considered a first-in-class melanocortin-receptor agonist for this indication. It is not approved for men, postmenopausal women, erectile dysfunction, or general libido enhancement; PT-141 sold as a "research peptide" outside this approved product is investigational/research-use and not an approved therapy.